Minims Tropicamida Bausch + Lomb Ireland (Tropicamide)

Tropicamide blocks muscarinic receptors in the iris sphincter muscle and ciliary body. This inhibition relaxes the sphincter, causing the pupil to open, and paralyzes the ciliary muscle, preventing accommodation, which together facilitate a clear view of intra‑ocular structures.

The specific dose and frequency of Minims Tropicamida are determined by the prescribing eye‑care professional based on the patient’s condition, age, and the intended procedure. The prescriber will provide exact instructions on how many drops to instill and how often.

Safety data for tropicamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To request Minims Tropicamida, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Tropicamide has a relatively rapid onset and short duration of action compared with agents such as phenylephrine or cyclopentolate. This makes it useful for brief diagnostic procedures, whereas longer‑acting mydriatics may be preferred for surgeries requiring prolonged dilation.

Minims Tropicamida should be stored at room temperature, protected from light and moisture, and kept in its original container. Ensure the cap is tightly closed to maintain sterility and potency until the product’s expiry date.

The medication is applied topically to the eye as a sterile drop. The prescriber will instruct the patient on the number of drops per eye, the interval between doses, and any necessary precautions such as avoiding contact with the bottle tip.

Serious risks include acute angle‑closure glaucoma, especially in patients with narrow‑angle anatomy, and systemic anticholinergic effects such as rapid heart rate, dry mouth, or urinary retention. Any signs of severe eye pain, vision loss, or systemic symptoms should prompt immediate medical attention.

Patients with known hypersensitivity to tropicamide or any component of the formulation, those with narrow‑angle or acute angle‑closure glaucoma, and individuals for whom mydriasis is contraindicated should avoid using Minims Tropicamida. The prescribing clinician will assess suitability.